Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.74 - $1.83 $539,744 - $1.33 Million
729,384 Added 34.67%
2,833,364 $2.51 Million
Q3 2022

Nov 14, 2022

BUY
$1.51 - $2.88 $840,766 - $1.6 Million
556,799 Added 35.99%
2,103,980 $3.3 Million
Q2 2022

Aug 15, 2022

BUY
$1.24 - $2.33 $647,911 - $1.22 Million
522,509 Added 50.99%
1,547,181 $3.11 Million
Q1 2022

May 16, 2022

BUY
$2.0 - $4.9 $157,458 - $385,772
78,729 Added 8.32%
1,024,672 $2.57 Million
Q4 2021

Feb 14, 2022

SELL
$4.65 - $7.23 $669,609 - $1.04 Million
-144,002 Reduced 13.21%
945,943 $5.66 Million
Q3 2021

Nov 12, 2021

SELL
$7.41 - $10.99 $932,192 - $1.38 Million
-125,802 Reduced 10.35%
1,089,945 $8.99 Million
Q2 2021

Aug 16, 2021

BUY
$6.35 - $10.0 $719,353 - $1.13 Million
113,284 Added 10.28%
1,215,747 $11.8 Million
Q1 2021

May 17, 2021

SELL
$7.03 - $16.51 $1.22 Million - $2.87 Million
-173,671 Reduced 13.61%
1,102,463 $9.12 Million
Q4 2020

Feb 16, 2021

BUY
$5.76 - $11.95 $347,414 - $720,764
60,315 Added 4.96%
1,276,134 $8.71 Million
Q3 2020

Nov 16, 2020

BUY
$6.17 - $18.82 $2.41 Million - $7.34 Million
390,089 Added 47.24%
1,215,819 $13.6 Million
Q2 2020

Aug 14, 2020

BUY
$1.73 - $6.76 $540,095 - $2.11 Million
312,194 Added 60.79%
825,730 $5.19 Million
Q1 2020

May 14, 2020

BUY
$1.57 - $4.76 $25,452 - $77,169
16,212 Added 3.26%
513,536 $944,000
Q4 2019

Feb 14, 2020

SELL
$1.45 - $4.17 $65,052 - $187,082
-44,864 Reduced 8.27%
497,324 $1.68 Million
Q3 2019

Nov 14, 2019

BUY
$2.05 - $2.69 $191,568 - $251,375
93,448 Added 20.82%
542,188 $1.16 Million
Q2 2019

Aug 15, 2019

BUY
$2.67 - $4.38 $1.2 Million - $1.97 Million
448,740 New
448,740 $1.2 Million

Others Institutions Holding SRNE

About Sorrento Therapeutics, Inc.


  • Ticker SRNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 449,952,000
  • Market Cap $148M
  • Description
  • Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...
More about SRNE
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.